```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "Parkin",
        "Protein_Change": {
          "ref": "K",
          "alt": "N",
          "position": "27"
        },
        "variant_string_id": "Parkin K27N"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkin is an E3-ubiquitin ligase belonging to the RBR (RING-InBetweenRING-RING family), and is involved in the neurodegenerative disorder Parkinson's disease. Autosomal recessive juvenile Parkinsonism... is directly linked to mutations in the parkin gene. However, the molecular mechanisms of Parkin dysfunction in the disease state remain to be established.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as loss of E3 ubiquitin ligase activity of Parkin leading to neurodegeneration."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses autoubiquitination assays to assess the ligase activity of Parkin variants.",
          "judgment": "Yes",
          "reasoning": "Autoubiquitination assays are relevant because they directly assess the E3 ubiquitin ligase activity of Parkin, which is the core function affected in the disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Western blot analysis of autoubiquitination assays of WT Parkin (WT) and \\u0394Ubl-Parkin (\\u0394UbID) reveal inhibition of Parkin autoubiquitination by the Ubl domain... pathogenic point mutations render Parkin active for autoubiquitination while R51P does not... Experiments were repeated three times.",
          "judgment": "Yes",
          "reasoning": "The study included WT (negative) controls and also shows increased activity in a deletion mutant. The text mentions the experiments were repeated indicating replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Furthermore, we show that pathogenic mutations disrupt this autoinhibition, resulting in a constitutively active molecule. The paper shows that the R51P variant behaves like WT.",
          "judgment": "Yes",
          "reasoning": "The paper uses R51P a 'silent' mutation as a control. The paper also uses known pathogenic variants to show activity.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The paper shows images and relative quantifications but does not provide statistical analysis or calculate OddsPath.",
          "judgment": "No",
          "reasoning": "The paper does not report statistical analyses that would allow calculation of OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Western blot analysis of Parkin autoubiquitination shows that pathogenic point mutations render Parkin active for autoubiquitination while R51P does not.",
          "judgment": "Yes",
          "reasoning": "The paper uses WT and R51P. A single 'silent' variant for a benign control.",
          "next_step_or_outcome": null
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The study uses an autoubiquitination assay, includes WT, 'silent', and pathogenic variants as controls, but does not present OddsPath calculations or strong statistical validation. Therefore, the final evidence strength is PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "Parkin",
        "Protein_Change": {
          "ref": "R",
          "alt": "3",
          "position": "33"
        },
        "variant_string_id": "Parkin R333"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkin is an E3-ubiquitin ligase belonging to the RBR (RING-InBetweenRING-RING family), and is involved in the neurodegenerative disorder Parkinson's disease. Autosomal recessive juvenile Parkinsonism... is directly linked to mutations in the parkin gene. However, the molecular mechanisms of Parkin dysfunction in the disease state remain to be established.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as loss of E3 ubiquitin ligase activity of Parkin leading to neurodegeneration."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses autoubiquitination assays to assess the ligase activity of Parkin variants.",
          "judgment": "Yes",
          "reasoning": "Autoubiquitination assays are relevant because they directly assess the E3 ubiquitin ligase activity of Parkin, which is the core function affected in the disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Western blot analysis of autoubiquitination assays of WT Parkin (WT) and \\u0394Ubl-Parkin (\\u0394UbID) reveal inhibition of Parkin autoubiquitination by the Ubl domain... pathogenic point mutations render Parkin active for autoubiquitination while R51P does not... Experiments were repeated three times.",
          "judgment": "Yes",
          "reasoning": "The study included WT (negative) controls and also shows increased activity in a deletion mutant. The text mentions the experiments were repeated indicating replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Furthermore, we show that pathogenic mutations disrupt this autoinhibition, resulting in a constitutively active molecule. The paper shows that the R51P variant behaves like WT.",
          "judgment": "Yes",
          "reasoning": "The paper uses R51P a 'silent' mutation as a control. The paper also uses known pathogenic variants to show activity.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The paper shows images and relative quantifications but does not provide statistical analysis or calculate OddsPath.",
          "judgment": "No",
          "reasoning": "The paper does not report statistical analyses that would allow calculation of OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Western blot analysis of Parkin autoubiquitination shows that pathogenic point mutations render Parkin active for autoubiquitination while R51P does not.",
          "judgment": "Yes",
          "reasoning": "The paper uses WT and R51P. A single 'silent' variant for a benign control.",
          "next_step_or_outcome": null
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The study uses an autoubiquitination assay, includes WT, 'silent', and pathogenic variants as controls, but does not present OddsPath calculations or strong statistical validation. Therefore, the final evidence strength is PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "Parkin",
        "Protein_Change": {
          "ref": "R",
          "alt": "P",
          "position": "42"
        },
        "variant_string_id": "Parkin R42P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkin is an E3-ubiquitin ligase belonging to the RBR (RING-InBetweenRING-RING family), and is involved in the neurodegenerative disorder Parkinson's disease. Autosomal recessive juvenile Parkinsonism... is directly linked to mutations in the parkin gene. However, the molecular mechanisms of Parkin dysfunction in the disease state remain to be established.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as loss of E3 ubiquitin ligase activity of Parkin leading to neurodegeneration."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses autoubiquitination assays to assess the ligase activity of Parkin variants.",
          "judgment": "Yes",
          "reasoning": "Autoubiquitination assays are relevant because they directly assess the E3 ubiquitin ligase activity of Parkin, which is the core function affected in the disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Western blot analysis of autoubiquitination assays of WT Parkin (WT) and \\u0394Ubl-Parkin (\\u0394UbID) reveal inhibition of Parkin autoubiquitination by the Ubl domain... pathogenic point mutations render Parkin active for autoubiquitination while R51P does not... Experiments were repeated three times.",
          "judgment": "Yes",
          "reasoning": "The study included WT (negative) controls and also shows increased activity in a deletion mutant. The text mentions the experiments were repeated indicating replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Furthermore, we show that pathogenic mutations disrupt this autoinhibition, resulting in a constitutively active molecule. The paper shows that the R51P variant behaves like WT.",
          "judgment": "Yes",
          "reasoning": "The paper uses R51P a 'silent' mutation as a control. The paper also uses known pathogenic variants to show activity.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The paper shows images and relative quantifications but does not provide statistical analysis or calculate OddsPath.",
          "judgment": "No",
          "reasoning": "The paper does not report statistical analyses that would allow calculation of OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Western blot analysis of Parkin autoubiquitination shows that pathogenic point mutations render Parkin active for autoubiquitination while R51P does not.",
          "judgment": "Yes",
          "reasoning": "The paper uses WT and R51P. A single 'silent' variant for a benign control.",
          "next_step_or_outcome": null
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The study uses an autoubiquitination assay, includes WT, 'silent', and pathogenic variants as controls, but does not present OddsPath calculations or strong statistical validation. Therefore, the final evidence strength is PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "Parkin",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "46"
        },
        "variant_string_id": "Parkin A46P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkin is an E3-ubiquitin ligase belonging to the RBR (RING-InBetweenRING-RING family), and is involved in the neurodegenerative disorder Parkinson's disease. Autosomal recessive juvenile Parkinsonism... is directly linked to mutations in the parkin gene. However, the molecular mechanisms of Parkin dysfunction in the disease state remain to be established.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as loss of E3 ubiquitin ligase activity of Parkin leading to neurodegeneration."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses autoubiquitination assays to assess the ligase activity of Parkin variants.",
          "judgment": "Yes",
          "reasoning": "Autoubiquitination assays are relevant because they directly assess the E3 ubiquitin ligase activity of Parkin, which is the core function affected in the disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Western blot analysis of autoubiquitination assays of WT Parkin (WT) and \\u0394Ubl-Parkin (\\u0394UbID) reveal inhibition of Parkin autoubiquitination by the Ubl domain... pathogenic point mutations render Parkin active for autoubiquitination while R51P does not... Experiments were repeated three times.",
          "judgment": "Yes",
          "reasoning": "The study included WT (negative) controls and also shows increased activity in a deletion mutant. The text mentions the experiments were repeated indicating replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Furthermore, we show that pathogenic mutations disrupt this autoinhibition, resulting in a constitutively active molecule. The paper shows that the R51P variant behaves like WT.",
          "judgment": "Yes",
          "reasoning": "The paper uses R51P a 'silent' mutation as a control. The paper also uses known pathogenic variants to show activity.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The paper shows images and relative quantifications but does not provide statistical analysis or calculate OddsPath.",
          "judgment": "No",
          "reasoning": "The paper does not report statistical analyses that would allow calculation of OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Western blot analysis of Parkin autoubiquitination shows that pathogenic point mutations render Parkin active for autoubiquitination while R51P does not.",
          "judgment": "Yes",
          "reasoning": "The paper uses WT and R51P. A single 'silent' variant for a benign control.",
          "next_step_or_outcome": null
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The study uses an autoubiquitination assay, includes WT, 'silent', and pathogenic variants as controls, but does not present OddsPath calculations or strong statistical validation. Therefore, the final evidence strength is PS3_supporting."
      }
    ]
  }
```